DOCSLIB.ORG

CHRONOLOGIE Du COVID-19

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

CHRONOLOGIE du COVID-19 Ø 1997 : Donald Rumsfeld devient « chairman » de Gilead Science Il sera Secrétaire à la Défense des États-Unis entre 2001 et 2006 dans l'administration du président George W. Bush. Éléments intéressants qui permettent de comprendre les liens étroits entre l’industrie pharmaceutique et le complexe militaro-industriel : 1. En 1997, Gilead a lancé des recherches sur le bioterrorisme en travaillant sur une molécule appelée Cidofovir, qui était traditionnellement utilisée dans le traitement de la variole. 2. En 1998, Donald Rumsfeld a convaincu Bill Clinton de bombarder une usine d'Al-Shifa, un rival et concurrent de Gilead au Soudan, sous prétexte que la société fabriquait des armes chimiques pour Al-Qaida. 3. En 2001, alors que Donald Rumsfeld était Secrétaire à la Défense, Gilead Sciences fournira des médicaments anti- varioliques au Pentagone lors des attaques à l’anthrax. https://greatgameindia.com/gilead-sciences-the-coronavirus-vaccine- manufacturer-accused-of-bioterrorism/ https://www.gilead.com/news-and-press/press-room/press- releases/1997/1/donald-h-rumsfeld-named-chairman-of-gilead-sciences https://fr.wikipedia.org/wiki/Donald_Rumsfeld https://www.thelastamericanvagabond.com/all-roads-lead-dark-winter/ Voir plus bas (2009) : Gilead et le scandale du Tamiflu - Articles divers 1 Ø Juin 2001 : Exercice de simulation d’attaque à l’anthrax organisé par les autorités américaines En juin 2001, a lieu un exercice de simulation d’attaque à l’anthrax appelé Dark Winter. Le scénario est en partie réalisé par Robert Kadlec qui lui donne son nom de code. Des attaques à l’anthrax auront lieu une semaine après les attentats du 11 septembre 2001. Robert Kadlec sera, le 18 août 2017, nommé par Trump Assistant Secretary of Health and Human Services (Preparedness and Response). À partir de janvier 2020, il aura en charge de préparer la réponse des USA à la crise du Covid 19. https://www.thelastamericanvagabond.com/all-roads-lead-dark-winter/ Extraits de l’article de Whitney Webb sur le sujet (traduction réalisée par l’Idiot du Village) : « Les dirigeants de deux simulations de pandémie controversées qui ont eu lieu quelques mois avant la crise du Coronavirus - Event 201 et Crimson Contagion - partagent une histoire commune, la simulation de guerre biologique Dark Winter de 2001. Dark Winter n'a pas seulement prédit les attaques à l'anthrax de 2001, mais certains de ses participants avaient une connaissance préalable de ces attaques. Pourtant, en examinant non seulement ces incidents de biosécurité à Fort Detrick, mais aussi les attaques à l'anthrax de 2001 et l'épidémie actuelle de Covid-19, un autre point commun étrange ressort : un exercice de jeux de guerre de haut niveau s'est déroulé en juin 2001 qui a étrangement prédit non seulement les attaques à l'anthrax, mais aussi le récit initial de ces attaques par le gouvernement et bien plus encore. 2 Cet exercice de juin 2001, connu sous le nom de "Dark Winter", a également prédit de nombreux aspects de la réponse du gouvernement à la pandémie, qui ont ensuite réapparu dans la simulation d'octobre dernier "Event 201", qui a prédit une pandémie mondiale causée par un nouveau Coronavirus juste quelques mois avant l'épidémie de Covid-19. En outre, le gouvernement américain allait diriger sa propre série de simulations de pandémie, appelée "Crimson Contagion", qui prévoyait également certains aspects de l'épidémie de Covid-19 et de la réponse du gouvernement. Après une enquête plus approfondie, les principaux responsables de l'événement 201 et de Crimson Contagion, non seulement ont des liens profonds et de longue date avec les services de renseignement américains et le ministère américain de la défense, mais ils ont tous participé à l'exercice Dark Winter de juin 2001. Certaines de ces mêmes personnes ont également joué un rôle dans l'enquête "sabotée" du FBI sur les attaques à l'anthrax qui ont suivi et s'occupent maintenant des principaux aspects de la réponse du gouvernement américain à la crise Covid-19. L'un de ces individus, Robert Kadlec, a récemment été chargé de l'ensemble des efforts de réponse du Département américain de la santé et des services sociaux (HHS) à la crise du Covid-19, malgré le fait qu'il ait été récemment et directement responsable des actions qui ont inutilement infecté les Américains avec le Covid-19. (…) D'autres acteurs majeurs de Dark Winter sont maintenant les principaux moteurs des programmes de surveillance de masse de "biodéfense" actuellement promus comme une solution technologique à la propagation du Covid-19, malgré les preuves que ces programmes aggravent en fait les foyers de pandémie. D'autres ont encore des liens étroits avec le délit d'initié qui s'est récemment produit au sein d'un groupe restreint de sénateurs américains concernant l'impact économique de Covid-19 et sont prêts à profiter 3 personnellement de contrats lucratifs pour développer non pas un seul, mais la majorité des traitements et vaccins expérimentaux Covid-19 actuellement en cours de développement par des entreprises américaines. (…) Le nom de l'exercice provient d'une déclaration faite par Robert Kadlec, qui a participé au scénario créé pour l'exercice, lorsqu'il déclare que le manque de vaccins antivarioliques pour la population américaine signifie que "l'hiver pourrait être très sombre pour l'Amérique". Kadlec, un vétéran de l'administration George W. Bush et un ancien lobbyiste pour les entrepreneurs du renseignement militaire, dirige maintenant la réponse du HHS au Covid-19 et a dirigé les exercices "Crimson Contagion" de l'administration Trump en 2019, qui simulaient une pandémie de grippe paralysante aux États-Unis, qui avait d'abord pris naissance en Chine. L'histoire professionnelle de Kadlec, son obsession de plusieurs décennies pour les scénarios d'attaques apocalyptiques par armes biologiques et les exercices Crimson Contagion eux-mêmes font l'objet de la troisième partie de cette série. (…) Une autre figure de Dark Winter impliquée dans l'affaire Amerithrax était l'actuel secrétaire adjoint pour la préparation et la réponse (ASPR) au ministère américain de la santé et des services sociaux (HHS), Robert Kadlec, qui est devenu conseiller en matière de guerre biologique auprès du Pentagone dirigé par Rumsfeld dans les jours qui ont suivi le 11 septembre. La biographie officielle de Kadlec indique qu'il a "contribué à l'enquête du FBI sur les attaques à l'anthrax", bien que l'on ne sache pas exactement quelles ont été ces contributions, à part avoir rencontré au moins une fois des scientifiques à Fort Detrick en novembre 2001. Quelles qu'aient été ses contributions, Kadlec a longtemps été un fervent partisan du récit officiel concernant Bruce Ivins, qu'il a qualifié de "scientifique dérangé" et de seul coupable des attentats. Kadlec a également utilisé le récit officiel sur Ivins pour affirmer que les armes biologiques ont été "démocratisées", ce qui signifie, selon 4 lui, que les agents pathogènes peuvent être utilisés par quiconque dispose de "quelques milliers de dollars" et de suffisamment de temps. Notamment, Kadlec n'est pas le seul personnage clé dans la réponse actuelle du gouvernement américain au Covid-19 à avoir des liens avec l'enquête bâclée du FBI, puisque l'actuel secrétaire du HHS, Alex Azar, a également participé à l'enquête du FBI. De plus, Azar a déclaré lors d'un point de presse à la Maison Blanche en 2018 qu'il avait été "personnellement impliqué dans une grande partie de la gestion de la réponse [aux attaques à l'anthrax]" en tant qu'avocat général du HHS à l'époque. » Voir aussi la vidéo de Withney Webb sur le même sujet (en anglais) : « Bioterror War Games, DARPA, Technocracy & COVID-1984 » https://www.youtube.com/watch?v=PDar_CtOzWM Autres sources : https://foreignpolicy.com/2020/04/01/coronavirus-pandemic-war-games- simulation-dark-winter/ https://off-guardian.org/2020/09/13/watch-covid-911-from-homeland-security- to-biosecurity/ Ø 18 septembre 2001 : Le scénario imaginé par Dark Winter et son mentor, Robert Kadlec, se réalise : les États-Unis font l’objet d’une attaque à l’anthrax dans plusieurs villes américaines. Le gouvernement accuse l’Irak d’être responsable de l’attaque. On apprendra plus tard que la souche de l’anthrax provenait d’un laboratoire américain de la défense (Fort Detrick). https://www.thelastamericanvagabond.com/all-roads-lead-dark-winter/ Ø 2001 : L'épidémiologiste Neil Ferguson de l'Imperial College de Londres est à l'origine des recherches controversées qui ont déclenché l'abattage massif de onze millions de moutons et de bovins lors de l'épidémie de fièvre 5 aphteuse de 2001. Il avait prédit que jusqu'à 150 000 personnes pourraient mourir. Il y a eu moins de 200 décès. Ø 2002 : Neil Ferguson prédit que jusqu'à 50 000 personnes mourraient probablement d'une exposition à la maladie de la vache folle au Royaume-Uni. Il n'y a eu que 177 décès dus à cette maladie. Ø 2005 : En 2005, Neil Ferguson a prédit que jusqu'à 150 millions de personnes pourraient être tuées par la grippe aviaire. Au final, seules 282 personnes sont mortes de la maladie dans le monde entre 2003 et 2009. Ø 22 août 2005 : Publication dans le Virology Journal d’une étude importante qui établit l’efficacité de l’hydroxychloroquine contre le SARS-CoV « Chloroquine is a potent inhibitor of SARS coronavirus infection and spread » : https://virologyj.biomedcentral.com/articles/10.1186/1743-422X-2-69 Sur le même sujet : « COVER UP: Fauci Approved Chloroquine, Hydroxychloroquine 15 Years Ago to Cure Coronaviruses; “Nobody Needed to Die” » : Extraits de l’article (traduction réalisée par L’Idiot du Village) : « Le Dr Anthony Fauci, dont les conseils d'"expert" au président Trump ont entraîné l'arrêt complet du plus grand moteur économique de l'histoire mondiale, sait depuis 2005 que la chloroquine est un inhibiteur efficace des coronavirus.
Recommended publications
  • Full Biography

    Full Biography

    Adaora Adimora United States Adaora Adimora is Professor of Medicine and Epidemiology at the University of North Carolina at Chapel Hill. She is a physician epidemiologist with more than 25 years of clinical experience in treating people with HIV infection. She received her MD from the Yale School of Medicine and MPH in epidemiology from the UNC Gillings School of Global Public Health, and completed a residency in Internal Medicine followed by a fellowship in Infectious Diseases at Albert Einstein/Montefiore Medical Center. She began her career as an Infectious Diseases physician at Harlem Hospital in New York City and moved to North Carolina where she initially worked for the state health department in the Communicable Disease Control Branch. She subsequently moved to the University of North Carolina, where she began her research career. She has led population-based studies and community-based research in HIV epidemiology and prevention. Her research focuses on social, behavioral, and biomedical factors that influence the risk of acquiring HIV and other sexually transmitted infections. She has helped trace the pathways between social forces, such as mass incarceration, in racial disparities in HIV infection in the US. She has also worked in Cameroon and served as principal investigator of the UNC Fogarty AIDS International Training and Research Program since its inception in 1998 until 2014. This program has trained scores of researchers from China, Malawi, and Cameroon. A fellow of the American College of Physicians and the Infectious Diseases Society of America (IDSA), she chairs the Women at Risk Committee for the NIH’s HIV Prevention Trials Network and is Immediate Past Chair of the HIV Medicine Association.
  • Sudden Price Spikes in Off-Patent Prescription Drugs: Special

    Sudden Price Spikes in Off-Patent Prescription Drugs: Special

    Sudden Price Spikes in Off-Patent Prescription Drugs: The Monopoly Business Model that Harms Patients, Taxpayers, and the U.S. Health Care System Special Committee on Aging United States Senate Senator Susan M. Collins (R-ME), Chairman Senator Claire McCaskill (D-MO), Ranking Member December 2016 CONTENTS Executive Summary ........................................................................................................................ 3 Chapter 1. Background ................................................................................................................ 12 I. Purpose and Scope of the Investigation ......................................................................... 12 II. An Overview: Drug Pricing in the United States .......................................................... 13 III. FDA Regulation of Pharmaceuticals .............................................................................. 21 A. New Drug Applications .............................................................................................. 22 B. Abbreviated New Drug Applications ......................................................................... 22 C. Controls on Importation.............................................................................................. 23 D. FDA Approval for Generics ....................................................................................... 24 IV. Increasing Drug Prices ................................................................................................... 27 A. Prescription
  • HIV/AIDS Guidelines

    HIV/AIDS Guidelines

    U.S. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents Panel Members and Consultants (Last updated July 10, 2019; last reviewed July 10, 2019) These guidelines were developed by the Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents (a working group of the Office of AIDS Research Advisory Council). Panel Co-Chairs Roy M. Gulick Weill Cornell Medicine, New York, NY H. Clifford Lane National Institutes of Health, Bethesda, MD Executive Secretary Alice K. Pau National Institutes of Health, Bethesda, MD Scientific Members Judith Aberg Icahn School of Medicine at Mount Sinai, New York, NY Adaora Adimora University of North Carolina School of Medicine, Chapel Hill, NC Allison Agwu Johns Hopkins University, Baltimore, MD Jason Baker Hennepin Healthcare & University of Minnesota, Minneapolis, MN Curt Beckwith Alpert School of Medicine, Brown University, Providence, RI Roger Bedimo University of Texas Southwestern & VA North Texas Health Care System, Dallas, TX R. Douglas Bruce Cornell Scott Hill Health Center, New Haven, CT Geetanjali Chander Johns Hopkins University School of Medicine, Baltimore, MD Jennifer Cocohoba University of California San Francisco, San Francisco, CA Susan Cu-Uvin Alpert School of Medicine, Brown University, Providence, RI Eric Daar Harbor-UCLA Medical Center, Torrance, CA Rajesh Gandhi Massachusetts General Hospital & Harvard Medical School, Boston, MA Edward Gardner Denver Public Health & University of Colorado, Denver,
  • Mechanisms for the Negative Effects of Internalized HIV-Related

    Mechanisms for the Negative Effects of Internalized HIV-Related

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Carolina Digital Repository EPIDEMIOLOGY AND PREVENTION Mechanisms for the Negative Effects of Internalized HIV-Related Stigma on Antiretroviral Therapy Adherence in Women: The Mediating Roles of Social Isolation and Depression Bulent Turan, PhD,* Whitney Smith, MPH,† Mardge H. Cohen, MD,‡ Tracey E. Wilson, PhD,§ Adaora A. Adimora, MD,k Daniel Merenstein, MD,¶ Adebola Adedimeji, PhD, MPH, MBA,# Eryka L. Wentz,** Antonina G. Foster, NP, MSN, MPH,†† Lisa Metsch, PhD,‡‡ Phyllis C. Tien, MD,§§ Sheri D. Weiser, MD, MPH,kk and Janet M. Turan, PhD, MPH† ART for whom data on medication adherence were available from Background: Internalization of HIV-related stigma may inhibit their last study visit between April 2013 and March 2014, when the ’ a person s ability to manage HIV disease through adherence to internalized stigma measure was initially introduced. treatment regimens. Studies, mainly with white men, have suggested an association between internalized stigma and suboptimal adher- Results: The association between internalized stigma and self- ence to antiretroviral therapy (ART). However, there is a scarcity of reported suboptimal ART adherence was significant for those in research with women of different racial/ethnic backgrounds and on racial/ethnic minority groups (AOR = 0.69, P = 0.009, 95% CI: mediating mechanisms in the association between internalized 0.52 to 0.91), but not for non-Hispanic whites (AOR = 2.15, P = stigma and ART adherence. 0.19, 95% CI: 0.69 to 6.73). Depressive symptoms, loneliness, and low perceived social support mediated the association between Methods: The Women’s Interagency HIV Study (WIHS) is internalized stigma and suboptimal adherence in the whole a multicenter cohort study.
  • Overcoming Barriers to Diversifying Clinical Trials: 2Nd Public Workshop

    Overcoming Barriers to Diversifying Clinical Trials: 2Nd Public Workshop

    POLICY AND GLOBAL AFFAIRS DIVISION Committee on Women in Science, Engineering, and Medicine SPEAKER BIOS (in alphabetical order by last name) Overcoming Barriers to Diversifying Clinical Trials: 2nd Public Workshop Webcast Live Here: https://www.nationalacademies.org/event/06-01-2021/overcoming-barriers-to- diversifying-clinical-trials-2nd-public-workshop June 1, 2021 | 10:00am-3:00 pm ET Adaora Adimora, Professor of Medicine, Division of Infectious Diseases, University of North Carolina School of Medicine; Professor of Epidemiology, Gillings School of Public Health Adaora Adimora is an American doctor and academic. She is the Sarah Graham Kenan Distinguished Professor of Medicine and professor of epidemiology at the University of North Carolina School of Medicine. Her research centers on the transmission of HIV, as well as other sexually transmitted infections (STIs), among minority populations. Her work has highlighted the importance of social determinants of HIV transmission and the need for structural interventions to reduce risk. In 2019, she became an elected member of the National Academy of Medicine in recognition of her contributions. She is a physician-epidemiologist with specialty training and extensive clinical experience in infectious diseases, particularly HIV, both in North Carolina and New York City. She received her B.A. from Cornell University in Psychology and her medical degree from the Yale University School of Medicine. She did her Internal Medicine internship and residency at Boston City Hospital and completed specialty training in Infectious Diseases at Montefiore Hospital in the Bronx, NY. Prior to coming to UNC, she served as assistant chief for science of the NC Health Department's Communicable Disease Control Section.
  • Using Antitrust Law to Challenge Turing's Daraprim

    Using Antitrust Law to Challenge Turing's Daraprim

    CARRIER ET AL._31-2 USING ANTITRUST LAW_FINAL FORMAT.2017-07-18 (DO NOT DELETE) 7/18/2017 2:38 PM USING ANTITRUST LAW TO CHALLENGE TURING’S DARAPRIM PRICE INCREASE Michael A. Carrier,† Nicole L. Levidow†† & Aaron S. Kesselheim††† ABSTRACT In 2015, notorious pharmaceutical entrepreneur Martin Shkreli make worldwide headlines. As CEO of Turing Pharmaceuticals, Shkreli increased the price of pyrimethamine (Daraprim) 5000 percent. Although Turing’s price hike on the unpatented drug was met with widespread outrage, few recognized that the company had recently changed its distribution system from one in which the drug was widely available to one in which supplies could be obtained from only a single source. This Article contends that Turing’s restricted distribution scheme for pyrimethamine, with its apparent lack of legitimate justifications, could form the basis of an antitrust violation. Turing appears to have monopoly power in engineering and maintaining a 5000 percent price increase, preventing hospitals from obtaining pyrimethamine, and ensuring the absence of FDA- approved substitutes for the drug. The company also appears to have engaged in exclusionary conduct when it changed its distribution system in a way that only made sense by blocking generic competition. Because the combination of monopoly power and exclusionary conduct is the hallmark of a monopolization claim, Turing’s behavior warrants close antitrust scrutiny. DOI: https://dx.doi.org/10.15779/Z383R0PS73 © 2016 Michael A. Carrier, Nicole L. Levidow & Aaron S. Kesselheim. † Michael A. Carrier is a Distinguished Professor at Rutgers Law School. †† Nicole L. Levidow is a Research Fellow with the Program On Regulation, Therapeutics, And Law (PORTAL) in the Department of Medicine, Division of Pharmacoepidemiology and Pharmacoeconomics, at Brigham and Women’s Hospital.

  • How the Energy Choice Affects Rural Nevadans

    House GOP prepares GOP leaders Senate harassment bill to consider Trump’s scramble to contain runs into opposition $15 billion clawback immigration rebellion from House PAGE 2 PAGE 4 PAGE 6 Volume 20, Issue 14 May 30-June 5, 2018 lasvegastribune.com How the energy choice affects rural Nevadans By Thomas Mitchell would amend the state Constitution, the people they serve for the people Part one of a two-part series it is back on the ballot this fall for they serve. So at a very fundamental One of the big questions linger- final voter approval, but now a level that is choice.” ing about a constitutional amend- coalition headed by NV Energy is None of the rules will be written ment on the November ballot that campaigning to defeat it. until and unless it passes again in would end electric power monopo- David Luttrell — general man- November and goes to lawmakers. lies and create an open competitive ager of the Lincoln County Power Luttrell said what is really going market for electricity is: Just how District No. 1, president of the Ne- on at this stage is a kind of record will it affect customers of rural vada Rural Electric Association and building and fact finding. Nevada’s power cooperatives? a member of the Governor’s Com- “If you look at some of the Question 3 on the 2016 Gen- mittee on Energy Choice — said comments of proponents of energy eral Election ballot — the Energy his power district has not joined the choice, one of the things they very Choice Initiative (ECI) — passed coalition opposing the initiative, but strongly believe is that existing by an overwhelming 72.4 percent to he is concerned the initiative’s im- utilities do not and are not allowed 27.6 percent.

  • The Relationship Between Discrimination and Missed HIV Care Appointments Among Women Living with HIV

    AIDS and Behavior (2020) 24:151–164 https://doi.org/10.1007/s10461-019-02522-8 ORIGINAL PAPER The Relationship Between Discrimination and Missed HIV Care Appointments Among Women Living with HIV Andrew E. Cressman1 · Chanelle J. Howe1 · Amy S. Nunn2 · Adaora A. Adimora3 · David R. Williams4,5 · Mirjam‑Colette Kempf6 · Aruna Chandran7 · Eryka L. Wentz7 · Oni J. Blackstock8 · Seble G. Kassaye9 · Jennifer Cohen10 · Mardge H. Cohen11 · Gina M. Wingood12,13 · Lisa R. Metsch12 · Tracey E. Wilson14 Published online: 2 May 2019 © Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Receiving regular HIV care is crucial for maintaining good health among persons with HIV. However, racial and gender disparities in HIV care receipt exist. Discrimination and its impact may vary by race/ethnicity and gender, contributing to disparities. Data from 1578 women in the Women’s Interagency HIV Study ascertained from 10/1/2012 to 9/30/2016 were used to: (1) estimate the relationship between discrimination and missing any scheduled HIV care appointments and (2) assess whether this relationship is efect measure modifed by race/ethnicity. Self-reported measures captured discrimina- tion and the primary outcome of missing any HIV care appointments in the last 6 months. Log-binomial models accounting for measured sources of confounding and selection bias were ft. For the primary outcome analyses, women experiencing discrimination typically had a higher prevalence of missing an HIV care appointment. Moreover, there was no statistically signifcant evidence for efect measure modifcation by race/ethnicity. Interventions to minimize discrimination or its impact may improve HIV care engagement among women.

  • Sudden Price Spikes in Off-Patent Prescription Drugs: the Monopoly Business Model That Harms Patients, Taxpayers, and the U.S

    Sudden Price Spikes in Off-Patent Prescription Drugs: The Monopoly Business Model that Harms Patients, Taxpayers, and the U.S. Health Care System Special Committee on Aging United States Senate Senator Susan M. Collins (R-ME), Chairman Senator Claire McCaskill (D-MO), Ranking Member December 2016 CONTENTS Executive Summary ........................................................................................................................ 3 Chapter 1. Background ................................................................................................................ 12 I. Purpose and Scope of the Investigation ......................................................................... 12 II. An Overview: Drug Pricing in the United States .......................................................... 13 III. FDA Regulation of Pharmaceuticals .............................................................................. 21 A. New Drug Applications .............................................................................................. 22 B. Abbreviated New Drug Applications ......................................................................... 22 C. Controls on Importation.............................................................................................. 23 D. FDA Approval for Generics ....................................................................................... 24 IV. Increasing Drug Prices ................................................................................................... 27 A. Prescription

  • Cronyism's Threat Donald Trump's Maine D. Keith

    20161024_cover61404-postal.qxd 10/18/2016 7:11 PM Page 1 November 7, 2016 $4.99 YUVAL LEVIN ELIANA JOHNSON RICHARD BROOKHISER Cronyism’s Threat Donald Trump’s Maine D. Keith Mano’s Craft The BlueWave DEMOGRAPHIC CHANGES ARE THREATENING TO TURN TRADITIONAL RED STATES BLUE. HOW DO REPUBLICANS SURVIVE? TIM ALBERTA www.nationalreview.com base_new_milliken-mar 22.qxd 10/18/2016 1:49 PM Page 1 SMALL BUSINESS IS TOO BIG TO FAIL The Job Creators Network Bring Small Businesses Back Bus tour has been hitting the streets to raise awareness about the plight of small business and the challenges facing American entrepreneurs. Overtaxation, overregulation, and lack of access to credit are stifling our biggest source of new jobs. TO FIND OUT MORE, AND TO SEE HOW YOUR CONGRESSIONAL LEADERS STACK UP IN THE FIGHT FOR SMALL BUSINESS, VISIT DEFENDMAINSTREET.COM TOC_QXP-1127940144.qxp 10/19/2016 2:41 PM Page 1 Contents NOVEMBER 7, 2016 | VOLUME LXVIII, NO. 20 | www.nationalreview.com BOOKS, ARTS ON THE COVER Page 26 & MANNERS The Blue Wave 39 THE FACTS ON IMMIGRATION Republicans have carried Mark Krikorian reviews We Wanted Workers: the white vote in every Unraveling the Immigration general election since 1968. Narrative, by George J. Borjas. But that’s not enough 40 DARK LOYALTIES anymore. The demographic Ronald Radosh reviews True Believer: Stalin’s Last American writing is on the wall; if the Spy, by Kati Marton. GOP continues to repel 42 THE DOWNSIDE OF non-whites, it will cease to ROMNEYISM Jason Willick reviews The Upside Tim Alberta be competitive.
  • Adimora Biosketch

    Adimora Biosketch

    Program Director/Principal Investigator (Last, First, Middle) : BIOGRAPHICAL SKETCH Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. DO NOT EXCEED FOUR PAGES. NAME POSITION TITLE Adaora Adimora Professor of Medicine eRA COMMONS USER NAME (credential, e.g., agency login) EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.) DEGREE INSTITUTION AND LOCATION MM/YY FIELD OF STUDY (if applicable) Cornell University BA 06/77 Medicine Yale University School of Medicine MD 05/81 Medicine Boston City Hospital Internship 06/82 Internal Medicine Boston City Hospital Residency 06/84 Infectious Diseases Montefiore / Albert Einstein College of Medicine Fellowship 06/86 Infectious Diseases UNC School of Public Health MPH 05/93 Epidemiology A. Positions and Honors Positions and Employment 1986-1988 Assistant Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons, New York, NY 1986-1988 Assistant Attending Physician, Harlem Hospital Center, New York, NY 9/88-11/88 Attending, Medical Division, Dorthea Dix Hospital, Raleigh, NC 1988-1989 Assistant Head, Communicable Disease Control Branch, Division of Health Services, North Carolina Department of Human Resources, Raleigh, NC 1989-1990 Assistant Chief for Science, Communicable Disease Control Section, Division of Epidemiology, North Carolina
  • Impact of Health Insurance, ADAP, and Income on HIV Viral Suppression Among US Women in the Women’S Interagency HIV Study, 2006–2009

    Impact of Health Insurance, ADAP, and Income on HIV Viral Suppression Among US Women in the Women’S Interagency HIV Study, 2006–2009

    EPIDEMIOLOGY AND PREVENTION Impact of Health Insurance, ADAP, and Income on HIV Viral Suppression Among US Women in the Women’s Interagency HIV Study, 2006–2009 Christina Ludema, PhD,* Stephen R. Cole, PhD,† Joseph J. Eron, Jr, MD,* Andrew Edmonds, PhD,† G. Mark Holmes, PhD,‡ Kathryn Anastos, MD,§ Jennifer Cocohoba, PharmD,k Mardge Cohen, MD,¶ Hannah L. F. Cooper, ScD,** Elizabeth T. Golub, PhD,†† Seble Kassaye, MS, MD,‡‡ Deborah Konkle-Parker, PhD,§§ Lisa Metsch, PhD,kk Joel Milam, PhD,¶¶ Tracey E. Wilson, PhD,*** and Adaora A. Adimora, MPH, MD*† Results: In 2006, 65% of women had Medicaid, 18% had private Background: Implementation of the Affordable Care Act motivates insurance, 3% had Medicare or other public insurance, and 14% assessment of health insurance and supplementary programs, such as reported no health insurance. ADAP coverage was reported by 284 the AIDS Drug Assistance Program (ADAP) on health outcomes of women (20%); 56% of uninsured participants reported ADAP HIV-infected people in the United States. We assessed the effects of coverage. After accounting for study site, age, race, lowest observed health insurance, ADAP, and income on HIV viral load suppression. CD4, and previous health insurance, the hazard ratio (HR) for Methods: We used existing cohort data from the HIV-infected unsuppressed viral load among those privately insured without participants of the Women’s Interagency HIV Study. Cox pro- ADAP, compared with those on Medicaid without ADAP (referent portional hazards models were used to estimate the time from 2006 group), was 0.61 (95% CI: 0.48 to 0.77). Among the uninsured, to unsuppressed HIV viral load (.200 copies/mL) among those with those with ADAP had a lower relative hazard of unsuppressed viral Medicaid, private, Medicare, or other public insurance, and no load compared with the referent group (HR, 95% CI: 0.49, 0.28 to insurance, stratified by the use of ADAP.